Antidepressant launched in Australia
A new antidepressant for major depression disorder has been launched in Australia, the first new treatment in almost five years.
Marketed as Brintellix, vortioxetine is a once-daily oral medication available in a dose range of 5-20mg.
Trials show that vortioxetine is effective in treating cognitive symptoms of depression in patients with severe depression, depressed patients with anxiety, elderly patients and those who have failed to respond to prior SSRI/SNRI therapy.
The drug targets both the serotonin transporter as well as a number of